ENTRESTO is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction.1
Prescribe ENTRESTO® to act directly on the heart and help improve cardiac function for your chronic HFrEF patients2.
ENTRESTO has a dual mode of action that targets two complementary HF pathways, neprilysin inhibition and RAAS inhibition1.
Watch the mechanism of action video below to gain a deeper understanding of ENTRESTO’s dual blockade3
Discover how ENTRESTO can improve the heart’s structure and function, and reverse cardiac remodelling2,4,5
Summary of the safety profile
The most commonly reported adverse events (AEs) during treatment with ENTRESTO were hypotension (17.6%), hyperkalaemia (11.6%) and renal impairment (10.1%). Angioedema was reported in patients treated with sacubitril/valsartan (0.5%).1
Common AE:
Anaemia, hypokalaemia, hypoglycaemia, dizziness, headache, syncope, vertigo, orthostatic hypotension, cough, diarrhoea, nausea, gastritis, renal failure (renal failure, acute renal failure), fatigue, asthenia.1
Very common AE:
Hyperkalaemia, hypotension, renal impairment.1
Adverse reactions are ranked by System organ class and then by frequency with the most frequent first, using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; RAAS, renin-angiotensin-aldosterone system.
References:
- ENTRESTO Summary of Product Characteristics. Accessed May 2024 at www.medicines.ie
- Januzzi JL Jr, et al. JAMA 2019;322(11):1085–1095.
- Diez J et al. Eur J Heart Fail 2016; 19 (2) 167-176.
- Desai AS, et al. JAMA 2019;322(11):1077–1084.
- Wang Y, et al. J Am Heart Assoc 2019;8(13):e012272.